European Medicines Agency PRIME status granted to adeno-associated virus (AAV)-RPGR gene therapy for treatment of inherited retinal disease X-linked retinitis pigmentosa (XLRP)

Currently there are no approved treatments for XLRP, and this gene therapy is designed to treat the most common form of the disease, caused by mutations in the RPGR gene, by slowing the retinal degeneration and preserving visual function.